Chronic Rhinosinusitis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Chronic Rhinosinusitis Overview

Chronic rhinosinusitis is defined by the presence of at least two out of four cardinal symptoms (i.e., facial pain/pressure, hyposmia/anosmia, nasal drainage, and nasal obstruction) for at least 12 consecutive weeks, in addition to objective evidence. Objective evidence of chronic rhinosinusitis may be obtained on physical examination (anterior rhinoscopy, endoscopy) or radiography, preferably from sinus computed tomography

“Chronic Rhinosinusitis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Rhinosinusitis Market.

The Chronic Rhinosinusitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Rhinosinusitis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Chronic Rhinosinusitis treatment therapies with a considerable amount of success over the years. Chronic Rhinosinusitis Key players such as – Lanier Biotherapeutics, Trellis Bioscience, Insmed Incorporated, Biohaven Pharmaceuticals, Regeneron Pharmaceuticals, Lyra Therapeutics, and others, are developing therapies for the Chronic Rhinosinusitis treatment 

• Chronic Rhinosinusitis Emerging therapies such as – LNR 125.38, TRL1068, Brensocatib, Rimegepant, Dupilumab, LYR-210, and others are expected to have a significant impact on the Chronic Rhinosinusitis market in the coming years.   
• In January 2022, Lyra Therapeutics initiated a 52-week, multicenter, phase III, randomized, blinded, controlled, parallel group with a 24-week treatment period followed by a safety extension phase with crossover or continued treatment to evaluate the efficacy and safety of LYR-210 compared with sham control for treatment in adults with CRS.
• In November 2022, Lyra Therapeutics reported its financial results for the third quarter ended September 30, 2022 and provided a corporate update. The Company is temporarily pausing enrollment in the ENLIGHTEN II Phase III trial of LYR-210 to align the trial with the availability of clinical supply, which it will manufacture in house

Route of Administration

Chronic Rhinosinusitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Chronic Rhinosinusitis Pipeline Therapeutics Assessment

• Chronic Rhinosinusitis Assessment by Product Type
• Chronic Rhinosinusitis By Stage and Product Type
• Chronic Rhinosinusitis Assessment by Route of Administration
• Chronic Rhinosinusitis By Stage and Route of Administration
• Chronic Rhinosinusitis Assessment by Molecule Type
• Chronic Rhinosinusitis by Stage and Molecule Type

DelveInsight’s Chronic Rhinosinusitis Report covers around products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Chronic Rhinosinusitis Drugs Under Different Phases of Clinical Development Include:

• LNR 125.38: Lanier Biotherapeutics
• TRL1068: Trellis Bioscience
• Brensocatib: Insmed Incorporated
• Rimegepant: Biohaven Pharmaceuticals
• Dupilumab: Regeneron Pharmaceuticals
• LYR-210: Lyra Therapeutics

Get a Free Sample PDF Report to know more about Chronic Rhinosinusitis Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/chronic-rhinosinusitis-pipeline-insight

Chronic Rhinosinusitis Pipeline Analysis:

The Chronic Rhinosinusitis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Rhinosinusitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Rhinosinusitis Treatment.
• Chronic Rhinosinusitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Rhinosinusitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Rhinosinusitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Chronic Rhinosinusitis product details are provided in the report. Download the Chronic Rhinosinusitis pipeline report to learn more about the emerging Chronic Rhinosinusitis therapies

Chronic Rhinosinusitis Pipeline Market Drivers

• Increasing demand for minimally invasive techniques
• Increasing awareness about the target disease and treatment

Chronic Rhinosinusitis Pipeline Market Barriers

• Time-consuming clinical trials
• Unknown cause of chronic rhinosinusitis

Scope of Chronic Rhinosinusitis Pipeline Drug Insight    

• Coverage: Global
• Key Chronic Rhinosinusitis Companies: Lanier Biotherapeutics, Trellis Bioscience, Insmed Incorporated, Biohaven Pharmaceuticals, Regeneron Pharmaceuticals, Lyra Therapeutics, and others
• Key Chronic Rhinosinusitis Therapies: LNR 125.38, TRL1068, Brensocatib, Rimegepant, Dupilumab, LYR-210, and others
• Chronic Rhinosinusitis Therapeutic Assessment: Chronic Rhinosinusitis current marketed and Chronic Rhinosinusitis emerging therapies
• Chronic Rhinosinusitis Market Dynamics: Chronic Rhinosinusitis market drivers and Chronic Rhinosinusitis market barriers 

Request for Sample PDF Report for Chronic Rhinosinusitis Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Chronic Rhinosinusitis drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services